Cyproheptadine in Schizophrenia

Evaluation the effect of Cyproheptadine on relieving the negative and positive symptoms of patients with schizophrenia or schizoaffective

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100127003210N22

Enrollment

Registered

2021-07-05

Start date

2021-07-23

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: receiving Cyproheptadine by dose of 8 mg per day in form of two 4mg tablet twice a day in addition to receiving risperidone 4-6 mg daily as an antipsychotic. Interv

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Ages 18-65 years Diagnosis of schizophrenia or schizoaffective disorder (Deppresive type) based on DSM-V Taking Risperidone as an Antipsychotic Fill in the consent

Exclusion criteria

Exclusion criteria: Antipsychotic treatment other than Risperidone History of non-response to second generation antipsychotic treatment Drug abuse Thyroid Disorder Pregnancy and Lactation

Design outcomes

Primary

Measure	Time frame
Positive and Negative Syndrome. Timepoint: At the beginning of the study, the first week, the second week, the fourth week, the sixth week. Method of measurement: PANSS Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnaz Kongi

Shahid Beheshti University of Medical Sciences

fariano.ko@gmail.com+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026